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Background. This work evaluates the role of subtype F human immunodeficiency virus type 1 (HIV-1) protease
(PR) substitutions L89M and L90M in viral replication and resistance to PR inhibitors (PIs).
Methods. Subtype B and F PR genes were subjected to site-directed mutagenesis, to create and reverse the
methionine at positions 89 and 90. Viruses were re-created in cell culture, and their replicative capacity was assessed
by fitness assay. Generated viruses were also phenotyped for PI resistance.
Results. The subtype F clone (89M90L) showed a replicative capacity comparable to that of the PI-susceptible
subtype B clone (89L90L) and was more fit than the L89M mutated subtype B clone (89M90L). Both 89M90M
subtype B and F clones presented the lowest fitness s values. The L89M mutation impacted phenotypic resistance
to all PIs in half of the subtype F isolates but not in the subtype B isolates. Subtype F isolates presented a phenotypic
profile similar to that of subtype B isolates when the M89L mutation was introduced.
Conclusion. The L89M mutation in subtype F viruses is a high genetic barrier to the accumulation of the
L90M resistance mutation and can function as a resistance mutation, depending on the presence of other poly-
morphisms in the subtype F PR backbone.
HIV-1 protease (PR) inhibitors (PIs) are crucial com-
ponents in combined antiretroviral therapy (or high-
ly active antiretroviral therapy [HAART]) for patients
with AIDS [1–4]. Seven different PIs have been ap-
proved by the United States Food and Drug Admin-
istration (FDA) and are available for clinical use: sa-
quinavir (SQV), ritonavir (RTV), indinavir (IDV), nel-
finavir (NFV), amprenavir (APV), lopinavir (LPV), and,
more recently, atazanavir (ATV) [5–7]. Despite the great
potency of HAART that includes at least 1 PI, resistant
strains can emerge from the viral population circulating
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in the infected individual and cause therapy failure [8–
11]. These resistant strains harbor the enzymes PR and
reverse transcriptase (RT) with amino acid substitutions
that confer resistance to the PIs and RT inhibitors (RTIs),
respectively [1, 10, 12–16].
Drug-resistance mutations have been characterized
extensively for subtype B strains of HIV-1 [10, 17]. The
primary resistance mutations appear to modify the
amino acids that interact directly with the PIs inside of
the catalytic pocket of the enzyme [18–20], whereas the
secondary, or compensatory, mutations occur mostly
outside of the active cleft of the enzyme, restoring its
plasticity and catalytic capacity, which is generally di-
minished by the presence of primary mutation(s) [12,
18, 21, 22].
Genotyping and phenotyping assays play an impor-
tant role in the characterization of the mutational pat-
terns responsible for drug resistance. Different inter-
pretation algorithms for drug-resistance genotyping have
been established on the basis of both phenotyping as-
says and clinical correlations between therapy failure
 at Escola Paulista M
edicina on O
ctober 16, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
1962 • JID 2005:191 (1 June) • Calazans et al.
Figure 1. Amino acid sequences of protease (PR) from viral clones. A, Consensus sequences of PR from HIV-1 subtypes B and F (sequences
obtained from Los Alamos HIV sequence databank), illustrating the molecular signatures of subtype F PRs. B, The polymorphic regions of amino acids
89 and 90, generated from PR inhibitor–susceptible subtype B (pNL4-3) and F (F13) clones by the mutagenized clones. C, Amino acid sequences from
3 treatment-naive isolates of subtype F (F18, F17, and F22) with their respective mutants at amino acid 89. The amino acids at positions 89 and 90
are depicted to the right of the clone name.
and viral strains carrying mutations [23–27]. The algorithms
are nevertheless based on observations made using subtype B
strains of HIV-1, and there is little information on non–subtype
B strains [6, 28–30]. The usefulness of these algorithms to the
study of isolates of non–subtype B strains, as well as to the
characterization of new, subtype-specific PI-resistance muta-
tions, still needs to be addressed. Substitutions frequently found
in PRs of non–subtype B isolates, so-called “molecular signa-
tures,” may also interfere with the PI-resistance phenotype pro-
duced by other mutations that are well characterized in subtype
B isolates.
Subtype F is the most prevalent (prevalence, 15%) non-B
HIV-1 subtype found in Brazil [31–33]. Recently, we genotyp-
ically and phenotypically characterized Brazilian clinical isolates
of HIV-1 of subtypes F and B infecting adults [34] and children
[35] in whom antiretroviral therapy failed. Surprisingly, we
observed discordant genotypic profiles among subtype F iso-
lates that were phenotypically resistant to NFV. In total, 7
(53.8%) of 13 NFV-resistant subtype B isolates carried the
L90M substitution, which was characterized as conferring in
vitro and in vivo primary resistance to SQV [16, 36] and NFV
[15]. Another 3 isolates (23%) carried the D30N mutation,
which is also related to NFV resistance [37]. Of the 5 NFV-
resistant subtype F isolates found, however, only 1 (20%) car-
ried the L90M substitution (none carried the D30N mutation).
All of the subtype F isolates carried a polymorphism at neigh-
boring amino acid position 89 (L89M) identical to that found
at position 90, which confers resistance to NFV. No subtype B
isolate harbored this latter polymorphism. In the present study,
the role of the L89M substitution in preventing the accumu-
lation of L90M in subtype F isolates is demonstrated, by use
of a series of recombinant viruses carrying different mutations
in fitness experiments.
MATERIALS AND METHODS
Cells and viruses. MT-4 cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum and an-
tibiotics (Invitrogen). The HIV-1 subtype B proviral clone
pNL4-3 [38] was used as the reference virus. The cDNA of
HIV-1 viral isolate TVGG13 [35] was used as the representa-
tive of HIV-1 subtype F (F13; GenBank accession number
AY145824). This isolate carries 11 amino acid differences in
comparison with the consensus subtype B PRs (figure 1), 7 of
which are the molecular signatures of subtype F PRs (F1 con-
sensus). In addition, 3 other subtype F clinical isolates from PI-
experienced patients were used: F17 (TVGG17), F18 (TVGG18),
and F22 (TVGG22) (GenBank accession numbers AY145825,
AY145826, and AY145832, respectively) (figure 1C). The re-
combination vector pHXB-2-Dpro was used for the phenotyp-
ing assay [39].
Polymerase chain reaction (PCR), cloning, and site-directed
mutagenesis. A 651-bp PR-coding sequence was amplified by
PCR from both F13 cDNA and the pNL4-3 plasmid, by use of
the primers RVP5 (5′-gggaagatctggccttcctacaaggg-3′) and RVP3
(5′-ggcaaatactggagtattgtatgg-3′), with a standard protocol [39].
The amplification products were cloned into the pCR4-TOPO
vector as instructed by the TOPO TA Cloning Kit manual (In-
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vitrogen). The cloned PR fragments were subjected to site-
directed mutagenesis, by use of the Quick Change Mutagenesis
Kit (Stratagene), to create or reverse the 89M polymorphism,
as well as to introduce the L90M mutation (primers are shown
in table A1 of the Appendix, which appears only in the elec-
tronic edition of the Journal). The other 3 PR genes from
subtype F clinical isolates (F17, F18, and F22) were cloned and
mutagenized at amino acid position 89, to revert the methi-
onine to leucine, by use of primers 89L/90L F and R. The L89I
mutation was also introduced into clones F13 and Bwt, which
carry either leucine or methionine at PR position 90 (table A1
of the Appendix, which appears only in the electronic edition
of the Journal). The putative mutagenized clones were con-
firmed through DNA sequencing in both directions, by use of
the BigDye Terminator Sequencing Kit and an ABI 3100 au-
tomated sequencer (Applied Biosystems).
Virus PR genotyping. Viral RNA was extracted with Trizol
Reagent (Invitrogen), and the PR gene was amplified and se-
quenced as described elsewhere [33]. PR sequences were edited
with DNAStar software and were submitted to the HIV-ge-
notyping algorithm of the HIV RT and Protease Sequence Da-
tabase (available at: http://hivdb.stanford.edu) [23].
Phenotyping assay. The determination of HIV-1 phenotypic
resistance to FDA-approved PR inhibitors (except ATV) was per-
formed using recombinant virus assay technology, as described
elsewhere [40], by use of PCR fragments of the PR region of the
clones generated by site-directed mutagenesis (figure 1). These
fragments were cotransfected into CD4+ T lymphocytes (MT-4)
with the linearized pHXB-2-Dpro plasmid [39]. Homologous
recombination led to generation of chimerical virus containing
the different PR sequences. The virus containing the Bwt 89L90L
PR was used to obtain the reference 50% effective concentration
(EC50) values during the phenotyping assay. The susceptibility of
chimerical virus to all PIs was determined, in 2 independent
assays with duplicates, by an MT-4-3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazoliumbromide (MTT)–based cell viability as-
say, as described elsewhere [40].
Growth competition experiments (fitness assay). Experi-
ments were performed as described elsewhere [41, 42], in the
absence of drugs in MT-4 cells. The assay consists of the co-
infection of cultures with known amounts of the virus to be
tested, together with a reference clone. These cocultures were
subjected to repeated bottleneck passages [43]. The ratio of the
2 viruses was quantified by a genotypic assay as follows: the
proportion of the competing variant with respect to the ref-
erence strain (Rn) is divided by its proportion in the initial
mixture (Ro), and its value (Rn/Ro) is plotted against the com-
petition passage, to derive the fitness vector [43, 44]. Each
competition assay was performed in duplicate by infecting MT-
4 cells with mixtures of the viruses to be tested (Bwt- and F13-
derived mutagenesis clones) with Bwt 89L90L (the reference
virus), at an initial ratio of 1:1. For each competition, 105 MT-
4 cells were infected with 104 50% cell culture infectious doses
(CCID50) of the virus tested and of the reference virus (MOI
for each virus, 0.05). The culture supernatant was harvested
when a cytophatic effect was evident (∼3–7 days after infection).
Fresh MT-4 cells were then infected with 50 mL of this super-
natant. A total of 5 passages were performed, as described be-
low, and aliquots were removed from the cultures at days 0, 7,
10, 13, 16, and 19 and were centrifuged; the supernatants were
stored at 80C for further quantitative analysis of genotypes.
We have developed a quantitative assay to determine the ratio
of the different competing genotypes found in each culture
passage by use of the ABI Prism Snapshot Multiplex Kit (Ap-
plied Biosystems). This kit is based on the dideoxy single-base
extension of an unlabeled oligonucleotide (or a set of oligo-
nucleotides; see table A1 of the Appendix, which appears only
in the electronic edition of the Journal). Each primer binds to
a complementary template in the presence of the 4 ddNTPs
labeled with different fluorophores and Taq DNA polymerase.
The polymerase extends the primer by 1 nt, adding a single
labeled ddNTP to its 3′ end. The sample reactions are electro-
phoresed in an ABI Prism 310 Genetic Analyzer, and data are
analyzed with GeneScan Analysis Software (version 3.1; ABI).
This methodology was validated using an artificial mixture of
wild-type and mutant cloned material, and a linear regression
curve was obtained for the different mixture ratios, with a
coefficient of correlation (R2) 10.98.
Segregation of fitness assay PRs and analysis of recom-
bination. Supernatant harvested on day 19 of the fitness assay
(viral competitions Bwt 89L90L F13 89L90L and Bwt 89L90L
 F13 89M90M) were submitted to viral RNA extraction, fol-
lowed by reverse-transcription PCR and cloning in a TOPO
TA Cloning kit (Invitrogen). Colony PCR for the PR gene was
performed and submitted to BclI endonuclease digestion. Re-
striction-negative clones were submitted to sequencing, fol-
lowed by sequence alignment and analysis of recombination,
by use of the RIP 1.9 beta test (http://www.hiv.lanl.gov/content/
hiv-db/RIPPER/RIP.html).
Clinical samples. Analysis of clinical samples was per-
formed with internal databases from the Laboratory of Retro-
virology of the Federal University of Sa˜o Paulo and the Mo-
lecular Virology Laboratory of the Federal University of Rio de
Janeiro. These databases include clinical information on treated
patients from different regions of Brazil, including treatment
regimens, CD4+ T lymphocyte and viral load counts, and re-
sistance genotyping profiles. For the viral isolates from infected
individuals without PI exposure (treatment-naive individuals),
we used the database of these 2 laboratories from BResNet [31].
The data on viral isolates from HIV-1–infected individuals with
exposure to NFV and/or SQV was also obtained from Caride
et al. [34] and Brindeiro et al. [35]. All data were collected
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Table 1. Distribution of amino acid mutations at positions 89 and 90 in treatment-
naive and treated HIV-1 subtype B and F isolates.
Mutation
Treatment naive Treated
Subtype Ba Subtype Fa Pb Subtype B Subtype F Pb
89L 1997 49 50 4
89M 24 69 !.0001 4 18 !.0001
90L 2021 118 41 21
90M 0 0 !.0001 13 1 .04
NOTE. Data are no. of isolates found with each mutation.
a Calculation based on data from the Stanford HIV sequence database (available at: http://
hivdb.stanford.edu/).
b P (Fisher’s exact test), , for contingency tables.ap 0.05 22
under the supervision of the Universities’ respective institu-
tional review boards.
Statistical analysis. All statistical analyses were performed
using Analyse-it (version 1.62) for the Microsoft Excel statistics
package. Sigmaplot software (version 8.0) was used to perform
linear regressions for the fitness assay and nonlinear regressions
(Hill’s dose-response curve) for phenotyping. We established
the significant values of resistance by use of a nonparametric
Mann-Whitney U test, for comparison between the quadru-
plicates of EC50 for each mutagenized virus and the quadru-
plicates of EC50 for the Bwt L89L90 drug-susceptible clone.
RESULTS
Genotypic frequencies of the L89M and L90M polymorphisms
in subtype B and F clinical samples. Seventy-six previously
genotyped clinical isolates of virus from NFV- or SQV-treated
individuals (54 from subtype B and 22 from subtype F) were
analyzed for the presence of the L89M and L90M polymor-
phisms (table 1). Since L89M is a characteristic molecular sig-
nature of subtype F PRs, we also analyzed its frequency (as well
as the frequency of L90M) in genotyped clinical samples from
treatment-naive infected individuals (2021 from subtype B and
118 from subtype F), obtained from the Stanford HIV Drug
Resistance Database (http://hivdb.stanford.edu/) [23].
To avoid misinterpretation of the L89M frequencies in differ-
ent subtypes due to its presence as a natural polymorphism of
subtype F, the frequencies were also analyzed in separate groups
of treatment-naive and PI (NFV and SQV)–treated individuals.
A significant difference was noted between the subtype B and F
samples from treated individuals (8% and 82% with L89M, in
subtype B and F samples, respectively; , Fisher’s exactP ! .0001
test), and a significant accumulation of L90M in subtype B sam-
ples was noted, with a low frequency of this mutation in subtype
F isolates (subtype B vs. subtype F, ). There was a sig-Pp .04
nificant increase in the prevalence of L89M when treatment-naive
subtype F isolates were compared with their treated counterparts
( ). Of note, the 89M90M PR genotype could not be foundPp .03
in our study, for any subtype. Some other studies (R.S.D., un-
published data) have found this genotype in the subtype F back-
bone, at a frequency of !1%. Nevertheless, the subtype F isolates
from treated individuals described here as carrying the L90M re-
sistance mutation have also accumulated the M89I polymorphism.
Relative replicative fitness of mutated viruses. After gen-
erating the viral stocks in cell culture by cotransfection of PR
amplicons with a pHXB-2-Dpro full-length clone, we per-
formed replicative competition experiments (fitness assay) be-
tween the PI-susceptible Bwt 89L90L viral clone and the other
clones herein described, in the absence of any PI (figure 2).
The Bwt 89M90L and Bwt 89M90M viruses replicate with a
lower capacity than does the reference virus, whereas the Bwt
89L90M mutant had minimally increased replicative fitness,
compared with that of Bwt 89L90L (figure 2A). The F13
89M90L and F13 89L90M clones had a replicative capacity
similar to that of the Bwt reference virus, but the latter reached
a positive fitness value (s) slightly higher than that of its F
89M90L counterpart (figure 2B). Both the F13 89L90L and F13
89M90M mutants showed a significant decrease in their rep-
licative capacity, compared with that of the Bwt reference virus
( and0.1622, respectively). Surprisingly, after bot-sp0.072
tleneck passages 1 (F13 89M90M) and 2 (F13 89L90L), these
clones recovered their replicative capacity and reached positive
fitness values ( and 0.0499, for F13 89L90L and F13sp 0.0459
89M90M, respectively).
To assess possible genetic causes of the fitness shift of viruses
F13 89L90L and F13 89M90M during the replicative compe-
tition experiment (fitness assay), we isolated and sequenced
clones of subtype F PR genes amplified from the mixture of
subtype B and F viruses at the last bottleneck event of the
fitness assay (day 19 virus passage). After PCR amplification
of cDNA obtained from viral RNA of culture supernatant, PR
gene amplicons were cloned directly into a pCR4.3 vector. Bac-
terial colonies carrying segregated PR genes were submitted to
colony PCR, followed by BclI enzyme digestion screening for
subtype F PRs. A BclI cut site can be found at nucleotide po-
sition 177 of the subtype B—but not subtype F—PR genes.
Eight of 22 clones and 12 of 24 clones analyzed for the F13
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Figure 2. Fitness vectors and corresponding fitness values of HIV-1 Bwt (A) and F13 (B) 89L90L, 89L90M, 89M90L, and 89M90M and of 89I90L
and 89I90M (C). In each competing passage, viral proportion (Rn) was compared with the ratio of the 2 viruses in the initial mixtures (Ro). The value
in each passage was used to derive the fitness vectors by linear regression. Details of all procedures involved are given in Materials and Methods.
For all lineages, the initial 1:1 viral competition rate was used in the calculation of the vectors. Vectors were drawn with data from 3 competing
passages. Slopes of fitness vectors (fitness values, s) for the HIV-1 clones are indicated for each clone in the plotting areas. The pNL4-3 Bwt L89L90
clone was used as a reference, under the assumption of an s value of 0.
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Figure 3. Recombination analysis (RIP 1.9 beta; Los Alamos HIV se-
quence database) in 3 sequences of 2 subtype F clones (A and B) segregated
from fitness assay Bwt 89L90L  F13 89L90L and 1 subtype F clone (C)
segregated from fitness assay Bwt 89L90L  F13 89M90M. The cloning
segregation was performed at bottleneck point 5 (day 19). The background
sequences for comparison were Bwt 89L90L–pNL4-3 (subtype B) and F13
89M90L (subtype F). RIP 1.9 beta analysis was performed with a window
size of 30 nt and a 90% threshold for statistical significance.
89L90L and F13 89M90M fitness assays, respectively, did not
digest with BclI and were subjected to DNA sequencing. Sub-
type F viruses isolated from the F13 89L90L fitness assay showed
2 different patterns of recombination with the standard Bwt
89L90L virus present in culture (figure 3A and 3B), as revealed
by the RIP 1.9 beta sequence analysis of recombination. For
the F13 89M90M fitness assay, only 1 pattern of recombination
between the subtype B and F viral clones originally present in
the culture was found (figure 3C).
The L89I mutation negatively impacted the replicative ca-
pacity of subtype B and F viruses carrying this mutation. This
effect was more drastic in subtype B viruses (Bwt 89I90L and
Bwt 89I90M) than in subtype F viruses (F13 89I90L and F13
89I90M), and it was also independent of the presence or ab-
sence of the L90M mutation (figure 2C). Both subtype F viruses
carrying the L89I substitution had a replicative capacity coef-
ficient (s) similar to that found for virus F 89M90M.
Phenotyping of clones from subtypes B and F. Recom-
binant viruses carrying the mutant PR genes were generated in
MT-4 cells, and all of the constructs were phenotyped in quad-
ruplicate for PI susceptibility by MT-4 cell–MTT-based cell
viability assay. The resulting EC50 values are shown in table 2.
To facilitate the comparison between the different clones from
subtypes B and F, we chose to establish the statistical signifi-
cance of resistance on the basis of the quadruplicate sampling
comparing the EC50 in the Bwt L89L90 clone (subtype B wild-
type clone) with those in the other clones tested. The L89M
mutation conferred significant (5.6-, 4.7-, and 6.2-fold) in-
creases in EC50 for IDV, NFV, and RTV, respectively, on F13
89M90L virus, compared with Bwt 89L90L virus. These val-
ues are comparable to the resistance values obtained with Bwt
89L90M virus: 2.8-, 3.8-, and 5.5-fold resistance, respectively.
In contrast, the Bwt 89M90L clone behaved in a way that was
phenotypically similar to the susceptible Bwt 89L90L virus.
The F13 89L90M clone showed a 6.4-, 6.5-, 7.5-, 23-, 5.1-,
and 3.9-fold resistance increase for SQV, IDV, NFV, RTV, APV,
and LPV, respectively. These values represent a 3.0-, 3.7-, 1.9-,
4.3-, 1.8-, and 2.6-fold increase over its counterpart, Bwt
89L90M, for the same drugs. The Bwt 89M90M and F13
89M90M clones showed divergent phenotypic behavior. There
was a significant increase in resistance in the Bwt 89M90M
clone, compared with that in the Bwt 89L90L clone (table 2),
with the exception of resistance to LPV. In contrast, there was
a significant decrease in resistance to RTV, NFV, and APV in
the Fwt 89M90M clone, compared with that in the Fwt 89M90L
clone. ( , Mann-Whitney U test).P ! .05
Virus clones of both subtypes carrying an isoleucine at amino
acid position 89 were also phenotypically characterized (table
2). This mutation was not able to confer any significant level
of resistance to the PIs analyzed. The coexistence of an L90M
substitution with the 89I residue did not modify this pattern
of PI susceptibility, for either subtype analyzed.
To explore the unexpected phenotype coded by the L89M
polymorphism in subtype F PR, we cloned the PR genes of 3
other clinical isolates, and the 89M signature (wild-type subtype
F signature) was reversed to 89L by site-directed mutagenesis.
All 89L reversed clones were phenotyped for PI resistance (table
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Table 2. Results of protease inhibitor phenotying assay for Bwt and F13 clones.
Virus, clone
Fold resistance, amean SD
SQV IDV RTV NFV APV LPV
Bwt
89L90L 1.00  0.127 1.00  0.625 1.00  0.124 1.00  0.314 1.00  0.192 1.00  0.159
89M90L 1.00  0.329 2.96  0.095 0.77  0.135 1.10  0.069 1.47  0.136 0.77  0.240
89L90M 2.12  0.480 2.80  0.871 3.82  0.819 5.46  0.956 2.90  0.173 1.48  0.239
89M90M 1.67  0.399 2.04  0.020 2.71  0.303 4.44  0.410 2.57  0.195 1.32  0.150
89I90L 0.71  0.085 0.90  0.076 0.77  0.136 0.93  0.067 0.91  0.075 NDb
89I90M 1.31  0.108 1.60  0.070 2.56  0.152 1.81  0.210 1.23  0.067 NDb
F13
89L90L 0.51  0.182 1.23  0.331 0.33  0.068 0.82  0.154 0.74  0.143 0.78  0.104
89M90L 2.06  0.237 5.60  0.150 4.74  1.387 6.20  0.556 4.47  0.337 3.44  0.607
89L90M 6.42  0.967 6.51  0.430 7.45  1.901 23.39  4.605 5.13  1.880 3.87  0.344
89M90M 0.85  0.256 2.42  1.101 2.48  0.212 2.80  0.828 2.08  0.528 0.90  0.111
89I90L 0.68  0.008 0.77  0.008 0.96  0.080 0.80  0.105 0.70  0.071 NDb
89I90M 1.59  0.165 1.33  0.238 3.91  0.481 2.47  0.104 1.00  0.053 NDb
F18
89L90L 1.33  0.126 0.60  0.215 2.91  0.681 4.78  0.885 1.51  0.278 1.94  0.300
89M90L 2.03  0.128 2.29  0.151 3.71  0.832 5.84  0.714 1.21  0.644 2.02  0.070
F17
89L90L 0.95  0.054 0.89  0.057 0.45  0.019 2.17  0.199 1.84  0.017 1.59  0.021
89M90L 0.82  0.060 0.63  0.049 1.74  0.167 1.38  0.119 1.22  0.140 1.09  0.023
F22
89L90L 0.79  0.026 0.49  0.020 1.32  0.060 1.00  0.106 0.44  018 0.93  0.688
89M90L 0.38  0.032 0.36  0.036 0.59  0.056 0.38  0.038 0.33  0.024 0.51  0.171
a APV, amprenavir; IDV, indinivir; LPV, lopinavir; ND, not determined; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir. Fold resistance
is calculated as (50% effective concentration [EC50] of sample virus)/(EC50 of reference virus Bwt 89L90L). Data represent the results
of quadruplicate experiments. Cut-off values of fold resistance with clinical significance, according to Harrigan et al. [45], are as
follows: SQV, 2.5; IDV, 3.0; RTV, 3.5; NFV, 4.0; APV, 2.5; LPV, 4.0. Fold resistance values higher than the cut-off value are highlighted
in bold.
b Phenotyping values for 89I clones were not determined for LPV.
2), together with their wild-type 89M counterparts. Isolates F13
and F18 showed a significant decrease in EC50 values for IDV,
RTV, NFV, APV, and IDV alone when 89M was reversed to
89L. In contrast, isolates F17 and F22 showed no significant
difference in EC50 values when 89M was reversed.
DISCUSSION
HIV-1 subtype F is found throughout South America [18], in
Romania, and in Central Africa. Since the beginning of the
1990s, surveys conducted in Brazil have identified subtype F
as the main non–subtype B isolate in that country. Subtype F
strains, together with their recombinant forms with subtype B,
account for 15% of HIV-1 infections in Brazil. The subtype F
consensus sequence differs from the US and Brazilian subtype
B consensus sequence at 8 positions (I15V, E35D, M36I, R41K,
R57K, Q61N, L63P, and L89M) [33].
Subtype F isolates are infrequently found to carry the L90M
NFV and SQV–resistance mutation in HIV-1–infected individ-
uals in whom therapy has failed [34, 35, 46]. The relative rep-
licative capacity of viruses carrying subtype F PRs with M89L
and L90M substitutions appears to be higher than those with
the PI-susceptible prototypic subtype F PR genotype 89M90L,
as shown here by fitness assay. However, the accumulation of
L90M appears to be constrained to the change in the 89M sub-
type F polymorphism. This hypothesis is supported by the poor-
est relative replicative capacity being found for F13 89M90M,
compared with that in the F13 89L90M and F13 89M90L virus
clones ( , vs. 0.0165 and 0.0018, respectively; seesp0.1622
figure 2B for details). This effect was more noticeable in subtype
F clones, since the s values obtained for the subtype B clone
counterparts did not show this difference (figure 2A). Fur-
thermore, a detailed search of the PI-susceptibility data in the
Stanford HIV sequence database [23] reveals the low clinical
prevalence (0.36%, or 6/1682 samples analyzed) of viruses car-
rying the 89M90M polymorphisms. None of these isolates be-
longed to subtype F, and, of 109 subtype F isolates deposited,
only 1 carried the L90M mutation together with a M89I poly-
morphism (isolate TVGG27 [35]).
Since the F13 89L90L and F13 89M90M viruses had low
replicative fitness, the M89I mutation could represent the best
in vivo alternative for the transient mechanism of generation
of L90M PRs from the original 89M90L subtype F PRs [8, 34,
35, 47]. Nevertheless, the fitness assay showed both F13 89I90M
and F13 89I90L viruses with no advantage over their counter-
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part F13 89M90M in their fitness s values (all surrounding
0.16). Moreover, there was no fold increase, in these 2 89I
F13 clones, in resistance to any PI analyzed. Together, the fitness
assay and PI-resistance data indicate the existence of L90M and
M89I mutations occurring in subtype F PRs as independent
genetic events. The emergence of an M89I mutation in the
backbone of a subtype F 89M90M virus is favored by the low
genetic barrier of a single GrA transition, which changes the
ATG codon of methionine to the ATA codon of isoleucine,
against a less probable ArT or ArC transversion, which could
generate a highly adapted subtype F 89L90M virus. The com-
mon GrA hypermutation that occurs in HIV sequences and
is caused by the activity of cellular enzymes such as APOBEC
3G [48–50] is another possible mechanism that could favor the
ATGrATA transition at codon 89 in subtype F PRs, generating
the 89I mutation, although at a low frequency.
A recovery of relative replicative capacity for the F13
89M90M and 89L90L clones was seen after bottleneck passages
2 and 3, respectively, in the fitness assay. The sequences obtained
from different segregated clones of PRs from these subtype F
virus subpopulations revealed a recombination event between
2 viruses of different subtypes (B and F). These recombinant
events have probably yielded more fit viruses, explaining the
fitness recovery by consequent alteration of the PR structure
and its residue interactions. The loss of some PR molecular
signatures of the subtype F backbone through genetic recom-
bination could be involved with the fitness recovery, but this
hypothesis needs to be further analyzed.
The Bwt 89L90M virus was more fit than the PI-susceptible
Bwt 89L90L, in contrast to the findings of Martinez-Picado et
al. [44]. They found a low relative replicative fitness of subtype
B viruses carrying L90M, compared with a wild-type virus (10%
less fit than wild type), although their theoretical mathematical
model used for fitness calculation may not adequately quantify
relative growth rates of different HIV-1 mutants, as stated in
their article.
The L89M signature of F13 in its original sequence could
confer a significant level of resistance to IDV, as expected [13,
51], but also, surprisingly, to RTV and NFV. The reversion of
the L89M mutation in subtype F isolates was able to confer a
significant decrease in EC50 to all 6 PIs analyzed. The same
phenotypic behavior was not observed for the subtype B clone
carrying L89M, which remained susceptible to PIs, with the
exception of IDV. The role of the L89M polymorphism in IDV
resistance in the subtype B backbone has already been dem-
onstrated by others [13, 49]. In contrast, the LrM change in
PR amino acid position 89 was previously described to have
no correlation with PI regimen failure [16], although only clin-
ical samples from subtype B were analyzed.
Interestingly, this 89M-related resistance is observed in only
half of the subtype F isolates (F13 and F18) analyzed in our
work, which indicates that other polymorphisms are involved
in this phenotypic behavior. Samples F17 and F22 did not
present significant levels of resistance to IDV, RTV, or NFV,
unlike their subtype F counterparts F13 and F18. This fact can
be partially explained by other polymorphisms found to differ
from those common subtype F signatures, such as the I72T
mutation, present in both F17 and F22, or the V15I and K70R
mutations (reversing the F molecular signature), present in F17
and F22, respectively. The question of whether the differences
between the sequences of clones F17 and F22 and the sequences
of clones F13 and F18 account for the phenotypic divergence
found still remains to be addressed.
Several studies [28–30, 34–47] have already demonstrated
different adaptive strategies of resistance-mutation accumula-
tion between subtype B and non–subtype B viruses, although
the amino acid substitutions described for non–subtype B vi-
ruses and conferring resistance to antiretrovirals were basically
the same as those described for subtype B viruses. The L89M
polymorphism in the subtype F PR backbone is mostly related
to the maintenance of viral fitness, and its presence as a mo-
lecular signature in the subtype F PR backbone confers a higher
genetic barrier to the accumulation of the L90M resistance
mutation. The L89M polymorphism is the most prevalent sig-
nature among treatment-naive non–subtype B isolates and ac-
counts for 98% of all PR sequences in the Stanford HIV se-
quence database. The same genetic barrier posed by L89M could
play a role in other non–subtype B isolates and needs to be
addressed in specific studies.
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